Home › Clear-cell metastatic renal cell carcinoma › Minnesota › Rochester
Clear-cell metastatic renal cell carcinoma clinical trials in Rochester, MN
4 studies for Clear-cell metastatic renal cell carcinoma are looking for participants at sites in and around Rochester (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
RecruitingPhase 3
- Research Site, Rochester
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RecruitingPhase 1/2
- Mayo Clinic Hospital, Methodist Campus, Research Pharmacy, Rochester
- Mayo Clinic Cancer Center Outpatient Pharmacy, Rochester
VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma
RecruitingPhase 2
- Mayo Clinic in Rochester, Rochester
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
RecruitingObservational study
- Mayo Clinic in Rochester, Rochester
Clear-cell metastatic renal cell carcinoma trials in other cities
- Baldwin Park, CA7 studies
- New York City, NY5 studies
- Dallas, TX5 studies
- Nashville, TN5 studies
- Cleveland, OH4 studies
- Waukegan, IL4 studies
- St. Louis, MO4 studies
- Ann Arbor, MI3 studies
- San Francisco, CA3 studies
- Queens, NY3 studies
- Houston, TX3 studies
- San Diego, CA3 studies
Other studies in Rochester
- Breast Cancer42 studies
- Non-Small Cell Lung Cancer37 studies
- Metastatic Cancer31 studies
- Cancer (all types)30 studies
- Ovarian Cancer29 studies
- Colorectal Cancer29 studies
- Multiple Myeloma24 studies
- Heart Failure22 studies
- Prostate Cancer22 studies
- Pancreatic Cancer22 studies
- Endometrial Cancer20 studies
- Lung Cancer20 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.